These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 11179903)

  • 1. Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor.
    Grigoryev DN; Long BJ; Njar VC; Brodie AH
    J Steroid Biochem Mol Biol; 2000 Dec; 75(1):1-10. PubMed ID: 11179903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function.
    Adam RM; Kim J; Lin J; Orsola A; Zhuang L; Rice DC; Freeman MR
    Endocrinology; 2002 Dec; 143(12):4599-608. PubMed ID: 12446587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
    Tan J; Sharief Y; Hamil KG; Gregory CW; Zang DY; Sar M; Gumerlock PH; deVere White RW; Pretlow TG; Harris SE; Wilson EM; Mohler JL; French FS
    Mol Endocrinol; 1997 Apr; 11(4):450-9. PubMed ID: 9092797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells.
    Yeap BB; Krueger RG; Leedman PJ
    Endocrinology; 1999 Jul; 140(7):3282-91. PubMed ID: 10385425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic activation of the androgen receptor by bombesin and low-dose androgen.
    Dai J; Shen R; Sumitomo M; Stahl R; Navarro D; Gershengorn MC; Nanus DM
    Clin Cancer Res; 2002 Jul; 8(7):2399-405. PubMed ID: 12114445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
    Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
    Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP.
    Warriar N; Pagé N; Koutsilieris M; Govindan MV
    Prostate; 1994 Apr; 24(4):176-86. PubMed ID: 8146066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms.
    Periyasamy S; Warrier M; Tillekeratne MP; Shou W; Sanchez ER
    Endocrinology; 2007 Oct; 148(10):4716-26. PubMed ID: 17615153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.
    Gregory CW; Johnson RT; Mohler JL; French FS; Wilson EM
    Cancer Res; 2001 Apr; 61(7):2892-8. PubMed ID: 11306464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
    Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
    BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor.
    Wang LG; Liu XM; Kreis W; Budman DR
    Biochem Pharmacol; 1998 May; 55(9):1427-33. PubMed ID: 10076535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.
    Grigoryev DN; Long BJ; Nnane IP; Njar VC; Liu Y; Brodie AM
    Br J Cancer; 1999 Oct; 81(4):622-30. PubMed ID: 10574247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
    Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
    Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells.
    Masiello D; Chen SY; Xu Y; Verhoeven MC; Choi E; Hollenberg AN; Balk SP
    Mol Endocrinol; 2004 Oct; 18(10):2388-401. PubMed ID: 15256534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.